Following approval by CRG, the July meetings of GMMMG and the Greater Manchester ICS Clinical Effectiveness and Governance Committee, and review by the GM Executive, the following updates have been made to GMMMG guidelines, formulary, and RAG list:

  • Finerenone for CKD in type 2 diabetes added as GREEN (specialist advice)
  • Semaglutide for overweight and obesity added as RED
  • Orodispersible morphine added as GREEN and GREY, only for use when specified criteria are met
  • Eptinezumab for preventing migraine added as RED
  • Hydrocortisone modified release capsules (Efmody) added as GREEN (following specialist initiation), only for patients not well controlled on standard release preparations and where specified criteria are met
  • Dapagliflozin for CKD in children added to paediatric RAG list as RED
  • Chloral hydrate and cloral betaine added to the RAG list only as RED
  • Asfotase alfa added to the RAG list only as RED

The formulary has also been updated to reflect relevant safety alerts and NICE guidelines. For full details, see the GMMMG decision summary for July 2023, or the formulary change log available on the formulary page.